PURPOSE: We present the rationale and design of the Zambian Exclusive Breast-feeding Study (ZEBS), a randomized trial evaluating the efficacy of short-duration exclusive breast-feeding (EBF) as a strategy to reduce postnatal human immunodeficiency virus (HIV) transmission while preserving the other health benefits of this important mode of infant feeding. METHODS:One thousand two hundred HIV-positive pregnant women were recruited in Lusaka, Zambia, and followed with their infants for 24 months. In addition to Nevirapine (NVP), all women received intensive and frequent clinic- and home-based counseling to support exclusive breast-feeding. When the infant was 1 week of age, half of the women were randomly assigned to a group encouraged to abruptly (<24 h) cease all breast-feeding at 4 months. The primary outcome of the experimental (randomized) comparison is HIV-free survival at 24 months. The design is also observational and will compare HIV transmission rates between those who do and do not adhere to the counseling intervention promoting exclusive breast-feeding. CONCLUSION: Our study aims to quantify the benefit-risk ratio of early cessation of exclusive breast-feeding to interrupt mother-to-child transmission of HIV with an intensive behavioral intervention and has both observational and experimental analytic approaches. Our study design assesses efficacy and also has a prominent applied component that if the intervention is effective, it will permit rapid and sustainable adoption within low-resource communities.
RCT Entities:
PURPOSE: We present the rationale and design of the Zambian Exclusive Breast-feeding Study (ZEBS), a randomized trial evaluating the efficacy of short-duration exclusive breast-feeding (EBF) as a strategy to reduce postnatal human immunodeficiency virus (HIV) transmission while preserving the other health benefits of this important mode of infant feeding. METHODS: One thousand two hundred HIV-positive pregnant women were recruited in Lusaka, Zambia, and followed with their infants for 24 months. In addition to Nevirapine (NVP), all women received intensive and frequent clinic- and home-based counseling to support exclusive breast-feeding. When the infant was 1 week of age, half of the women were randomly assigned to a group encouraged to abruptly (<24 h) cease all breast-feeding at 4 months. The primary outcome of the experimental (randomized) comparison is HIV-free survival at 24 months. The design is also observational and will compare HIV transmission rates between those who do and do not adhere to the counseling intervention promoting exclusive breast-feeding. CONCLUSION: Our study aims to quantify the benefit-risk ratio of early cessation of exclusive breast-feeding to interrupt mother-to-child transmission of HIV with an intensive behavioral intervention and has both observational and experimental analytic approaches. Our study design assesses efficacy and also has a prominent applied component that if the intervention is effective, it will permit rapid and sustainable adoption within low-resource communities.
Authors: Louise Kuhn; Moses Sinkala; M P H Chipepo Kankasa; Prisca Kasonde; Donald M Thea; Grace M Aldrovandi Journal: J Acquir Immune Defic Syndr Date: 2006-06 Impact factor: 3.731
Authors: Charles van der Horst; Charles Chasela; Yusuf Ahmed; Irving Hoffman; Mina Hosseinipour; Rodney Knight; Susan Fiscus; Michael Hudgens; Peter Kazembe; Margaret Bentley; Linda Adair; Ellen Piwoz; Francis Martinson; Ann Duerr; Athena Kourtis; A Edde Loeliger; Beth Tohill; Sascha Ellington; Denise Jamieson Journal: Contemp Clin Trials Date: 2008-09-07 Impact factor: 2.226
Authors: Katherine Semrau; Louise Kuhn; Daniel R Brooks; Howard Cabral; Moses Sinkala; Chipepo Kankasa; Donald M Thea; Grace M Aldrovandi Journal: Am J Obstet Gynecol Date: 2011-06-15 Impact factor: 8.661
Authors: Jan Walter; Mrinal K Ghosh; Louise Kuhn; Katherine Semrau; Moses Sinkala; Chipepo Kankasa; Donald M Thea; Grace M Aldrovandi Journal: J Infect Dis Date: 2009-11-15 Impact factor: 5.226
Authors: Matthew P Fox; Daniel Brooks; Louise Kuhn; Grace Aldrovandi; Moses Sinkala; Chipepo Kankasa; Mwiya Mwiya; Robert Horsburgh; Donald M Thea Journal: J Acquir Immune Defic Syndr Date: 2008-05-01 Impact factor: 3.731
Authors: Laura Heath; Susan Conway; Laura Jones; Katherine Semrau; Kyle Nakamura; Jan Walter; W Don Decker; Jason Hong; Thomas Chen; Marintha Heil; Moses Sinkala; Chipepo Kankasa; Donald M Thea; Louise Kuhn; James I Mullins; Grace M Aldrovandi Journal: PLoS One Date: 2010-04-20 Impact factor: 3.240
Authors: Matthew P Fox; Daniel R Brooks; Louise Kuhn; Grace Aldrovandi; Moses Sinkala; Chipepo Kankasa; Robert Horsburgh; Donald M Thea Journal: Int J Epidemiol Date: 2008-11-30 Impact factor: 7.196